Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov .
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov .

Dr. Elisaveta Voynova

Dr. Elisaveta Voynova

Scientific Review Officer



Biography

Division:
Division of Basic and Integrative Biological Sciences DTCS
Review Branch:
Cancer Diagnosis, Prevention & Therapeutics CDPT
Study Section:
Cancer Biotherapeutics Development (CBD) SBIR/STTR SEP CDPT12

Dr. Elisaveta Voynova received her Ph.D. in immunology from the Bulgarian Academy of Science, where she developed chimeric antibodies as novel immunotherapy for autoimmune disease. She then completed her postdoctoral training at the Autoimmunity and Functional Genomics Section of the National Institute of Allergy and Infectious Diseases (NIAID). Whilst at NIAID, she discovered a new immune cell type, an atypical NK cell, that contributes to the initiation and aggravation of autoimmunity and inflammation. After NIAID, Dr. Voynova joined a preclinical drug development group (R&D) at AstraZeneca Corporation. In 2020, Dr. Voynova joined the National Cancer Institute’s (NCI) T-cell Engineering Facility, where she developed a CAR-NK cell platform for preclinical treatment of T-cell malignancies. Dr. Voynova later managed the immunophenotyping unit of the NCI’s Clinical Research Correlatives Core, assisting the Center for Cancer Research clinical investigators with her expertise in translational research. Her scientific focus includes cancer, autoimmunity, and inflammation. 

 

Last updated: 09/24/2025 05:05